Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.

Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA, Hamil SH, Eggleton JC, Taylor RP.

J Immunol. 2006 Nov 15;177(10):7435-43.

2.

Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models.

Li Y, Williams ME, Cousar JB, Pawluczkowycz AW, Lindorfer MA, Taylor RP.

J Immunol. 2007 Sep 15;179(6):4263-71.

3.

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, Densmore JJ, Williams ME, Taylor RP.

J Immunol. 2004 Mar 1;172(5):3280-8.

5.

Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.

Klepfish A, Gilles L, Ioannis K, Rachmilewitz EA, Schattner A.

Ann N Y Acad Sci. 2009 Sep;1173:865-73. doi: 10.1111/j.1749-6632.2009.04803.x. Erratum in: Ann N Y Acad Sci. 2010 Aug;1204:198. Eliezer, Rachmilewitz [corrected to Rachmilewitz, Eliezer A]; Ami, Schattner [corrected to Schattner, Ami].

PMID:
19758239
7.
9.

Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study.

Itälä M, Geisler CH, Kimby E, Juvonen E, Tjonnfjord G, Karlsson K, Remes K.

Eur J Haematol. 2002 Sep;69(3):129-34.

PMID:
12406005
10.

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.

Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M.

Blood. 2001 Dec 1;98(12):3383-9.

11.

Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.

Pickartz T, Ringel F, Wedde M, Renz H, Klein A, von Neuhoff N, Dreger P, Kreuzer KA, Schmidt CA, Srock S, Schoeler D, Schriever F.

Exp Hematol. 2001 Dec;29(12):1410-6.

PMID:
11750099
12.

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.

Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, Emmerich B; German Chronic Lymphocytic Leukemia Study Group.

Blood. 2001 Sep 1;98(5):1326-31.

13.

Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells.

Mankaï A, Bordron A, Renaudineau Y, Martins-Carvalho C, Takahashi S, Ghedira I, Berthou C, Youinou P.

Cancer Res. 2008 Sep 15;68(18):7512-9. doi: 10.1158/0008-5472.CAN-07-6446.

14.

High-dose rituximab therapy in chronic lymphocytic leukemia.

Keating M, O'Brien S.

Semin Oncol. 2000 Dec;27(6 Suppl 12):86-90.

PMID:
11226005
15.

Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.

Aue G, Lindorfer MA, Beum PV, Pawluczkowycz AW, Vire B, Hughes T, Taylor RP, Wiestner A.

Haematologica. 2010 Feb;95(2):329-32. doi: 10.3324/haematol.2009.012484. Epub 2009 Aug 13.

16.

Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.

Mankaï A, Buhé V, Hammadi M, Youinou P, Ghedira I, Berthou C, Bordron A.

Ann N Y Acad Sci. 2009 Sep;1173:721-8. doi: 10.1111/j.1749-6632.2009.04614.x.

PMID:
19758221
17.

Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.

Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PW, van de Winkel JG, Taylor RP.

J Immunol. 2011 Sep 15;187(6):3438-47. doi: 10.4049/jimmunol.1101189. Epub 2011 Aug 12.

18.

Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL.

Klepfish A, Rachmilewitz EA, Kotsianidis I, Patchenko P, Schattner A.

QJM. 2008 Sep;101(9):737-40. doi: 10.1093/qjmed/hcn085. Epub 2008 Jul 23.

PMID:
18650226
19.

An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.

Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, Foley PL, Taylor RP.

Blood. 2003 Feb 1;101(3):1071-9. Epub 2002 Sep 5.

20.

Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients.

Tam CS, Otero-Palacios J, Abruzzo LV, Jorgensen JL, Ferrajoli A, Wierda WG, Lerner S, O'Brien S, Keating MJ.

Br J Haematol. 2008 Apr;141(1):36-40. doi: 10.1111/j.1365-2141.2008.07012.x.

PMID:
18324964

Supplemental Content

Support Center